World Alzheimer's Disease Therapeutics Analysis Report 2022: 101 Active Drugs - Market Insight, Epidemiology and Pipeline Assessment by Molecule Type, Route of Administration, Pipeline Phase - ResearchAndMarkets.com

20 Dec 2022
www.businesswire.com
Drug ApprovalPhase 2Phase 1
DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease TherapeuticsAlzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.
'Alzheimer\'s Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)'
Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.
Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.
Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.
Scope of the Report
The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).
The Alzheimer's Disease TherapeuticsAlzheimer's Disease Therapeutics Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The key insights of the report have been presented through the leading company shares.
Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report.
Key Target Audience
End Users (Hospitals and clinics)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms
Key Topics Covered:
1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Dashboard
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
4.1 Global, Region wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
5.1 Companies' Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
5.2.2 Elsal Co., Ltd.
5.2.3 BioVie
5.2.7 Novartis
5.2.10 Biogen
6. Alzheimer's disease background
6.1 AD Fact Sheet
6.2 Epidemiology
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
6.5 Unmet Needs
7. Therapeutics in Pipeline
7.1 Pipeline Scenario
7.2 Alzheimer's Therapeutics Comparative Review
8. Pipeline Analysis
9. Phase I therapeutics Overview
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.3 anle138b
9.4 ASN51
9.5 CMS121
9.6 IBC-Ab002
9.7 LX1001
9.10 ACU193
9.11 NIO752
9.12 ALN-APP
9.13 TB006
9.14 SNK01
9.16 GB-5001
9.17 AC-1202
9.18 SHR-1707
9.19 BEY2153
9.20 JNJ-40346527
9.22 NPT 2042
9.23 ALZ-101
10. Phase I/II therapeutics Overview
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProT/ PrimeMSKT
10.3 TB006
10.5 DNL593
10.6 BIIB080
10.7 E2814
10.8 Tdap
10.9 ACI-35.030/ JACI-35.054
10.10 ACI-24.060
10.11 IVL3003
11. Phase II therapeutics Overview
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.3 AL002
11.4 AL001
11.5 CT1812 (Elaya)
11.7 ATH-1017
11.8 T-817MA
11.9 Montelukast buccal film
11.10 ABBV-916
11.12 TB006
11.13 LY3372689
11.14 MW150
11.15 EX039
11.16 JNJ-42847922
11.19 NanoLithium NP03
11.20 AstroStem
11.24 ALZ-801
11.25 CY6463
11.27 T3D-959
11.28 PMZ-1620
11.29 GV1001
11.30 ACZ885
11.31 PQ912
11.32 APH-1105
11.33 SLS-005
11.34 Flos gossypii flavonoids
11.35 Human Mesenchymal Stem cells (MSCs)
11.36 JNJ-63733657
11.37 IGC-AD1
11.38 TW001
11.39 ABvac40
12. Phase II/III therapeutics Overview
12.1.1 Drug Description
12.1.2 Outcomes
12.4 AGB101
13. Phase III therapeutics Overview
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.4 Nilotinib BE
13.7 Remternetug
13.9 NE3107
13.11 GV-971
13.13 TRx0237
13.14 Semagludtide
13.15 BPDO-1603
13.16 AR1001
13.17 KarXT
13.18 AXS-05
14. Phase IV therapeutics Overview
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.4 GV-971
15. Preclinical Phase therapeutics Overview
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123
16. Pipeline analysis, By molecule type
16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type
17. Pipeline analysis, By Route of Administration
17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
For more information about this report visit https://www.researchandmarkets.com/r/wcw7f7
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.